Complex Regional Pain Syndrome (CRPS) was recently designated as a rare disorder by the United States Food & Drug Administration. A disease is considered rare if fewer than 200,000 people in the United States have it. This designation has already generated much greater interest than ever before in CRPS/RSD and is enticing pharmaceutical corporations to consider developing medicines to treat CRPS.
- There are two clinical trials in CRPS is recruiting right now.
- Interim report of RSDSA funded Genetic study investigating the risk of developing CRPS
- Read about a new Research Study funded by RSDSA
- Safety of Intravenous Neridronic Acid in CRPS: The aim of this trial is to investigate the safety of intravenous neridronic acid in patients with complex regional pain syndrome (CRPS)
- Stanford Current Research Studies: We have a number of research studies being conducted and we always need the help of both individuals with chronic pain, and individuals without chronic pain! The studies we are currently conducting are summarized in the table below.
- TARGET Post-Approval Study (TARGET PAS): A Post-Approval Study to Evaluate Targeted SCS Spinal Cord Stimulation (SCS) Dorsal Root Ganglion (DRG) Stimulation for the Management of Moderate to Severe Chronic, Intractable, Pain of the Lower Limbs Due to CRPS Types I and II
- To locate clinical trials in CRPS and RSD, visit clinicaltrials.gov
- To view our 20-year study, visit crpssurvey.org